SCHEMBL6050089

SCHEMBL6050089

O=C(CCCl)c1ccon1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 5/20 0.40
NCOR1 O75376 5/20 0.40
HDAC1 Q13547 5/20 0.40
HDAC2 Q92769 5/20 0.40
HDAC8 Q9BY41 5/20 0.40
CHRNA4 P43681 2/20 0.37
ALDH1A1 P00352 1/20 0.37
GAA P10253 1/20 0.37
RAPGEF3 O95398 1/20 0.33
RAPGEF4 Q8WZA2 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32
CHRM2 P08172 1/20 0.32
CHRM3 P20309 1/20 0.32
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
ATM Q13315 1/20 0.31
LMNA P02545 1/20 0.31
HPGD P15428 1/20 0.31
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6808143 0.81 HDAC3 (0.38) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL27407527 0.81 HSD17B3 (0.41) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL21669602 0.77 CHRNA4 (0.36) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL21646057 0.77 HDAC3 (0.46) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL6517408 0.76
SCHEMBL21645685 0.73 DAGLA (0.43) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL28273457 0.72 CHRNA4 (0.44) CHRNA4ALDH1A1GAARAPGEF3RAPGEF4
SCHEMBL22235185 0.72 HDAC3 (0.38) HDAC3NCOR1HDAC1HDAC2HDAC8
SCHEMBL1323514 0.70
SCHEMBL3737945 0.70 PDPK1 (0.46) HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1414802-B1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2006-04-26 EP disclosed
US-6887871-B2 Use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2005-05-03 US disclosed
EP-1263711-B1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2004-12-15 EP disclosed
US-20040176422-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase ASTRAZENECA AB (SE) 2004-09-09 US disclosed
EP-1414802-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE AstraZeneca AB (SE) 2004-05-06 EP disclosed
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives ASTRAZENECA AB (SE) 2003-08-21 US disclosed
WO-2003011830-A1 HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE ASTRAZENECA AB (SE) 2003-02-13 WO disclosed
EP-1263711-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2001062704-A1 NOVEL USE OF PHENYLHETEROALKYLAMINE DERIVATIVES ASTRAZENECA AB (SE) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040176422-A1 Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase NOS3, NOS1, NOS2 HDAC3 2865/4885NCOR1 1558/4885HDAC1 2954/4885
US-20030158185-A1 Novel use of phenylheteroakylamine derivatives NOS1, XDH, NOS2 HDAC3 2945/4885NCOR1 1955/4885HDAC1 1346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.